IUC26673-89

Abstract Code: IUC26673-89   Reducing adverse outcomes following local anaesthetic trans-perineal prostate biopsies Moshtael 1, M. Johnston 1, G. Crowther 1, J. Brewin 1 (1) Department of Urology, Salisbury NHS Foundation Trust, BSW Hospitals Group, Salisbury, UK...

IUC26669-94

Abstract Code: IUC26669-94   The LDR BURST Trial: A Randomised Comparison of Toxicity Outcomes following LDR Brachytherapy vs 5-Fraction SBRT with a Rectal Spacer for Localised Prostate Cancer Hayhurst 1, S. Uribe-Lewis 2, J. Uribe 2, C. Mikropoulos 2, S. Otter...

IUC26667-92

Abstract Code: IUC26667-92   Assessment of QRISK®3 and Major Cardiovascular Events in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with ADT ± ARPI ± Docetaxel: A Retrospective Cohort Study Alom 1, A. Kutty 1, G. Neola 1, L. Pedapati 1, A....

IUC26665-90

Abstract Code: IUC26665-90   Global inequalities in prostate cancer incidence and mortality: an ecological analysis Hosseini 1, Y. Vaez-Gharamaleki 1, A. Motamedi 1 (1) Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz –...

IUC26663-88

Abstract Code: IUC26663-88   Real-world ARASENS triplet therapy in high-volume mHSPC: a single-centre cohort M.P. Juan Gonzalez 1, C. Martinez Martinez 1, A.J. Montalban Valverde 1, P.A. Barranzuela Decoll 1, Y. El Farh Boumajdil 1, E.J. Soria Hernandez 1, B....

IUC26662-87

Abstract Code: IUC26662-87   Ultra-low PSA as a real-world indicator of androgen receptor pathway inhibitors (ARPI) treatment response in metastatic prostate cancer Ghigeanu 1, I. Bogatu 2, M.A. Barbu 3 (1) Bucharest Institute of Oncology – Romania, (2)...
error: Content is protected !!